Neovasc (TSX:NVCN) Construction In Progress : C$0.00 Mil (As of Dec. 2022)

View and export this data going back to 2001. Start your Free Trial

What is Neovasc Construction In Progress?

Neovasc Construction In Progress Historical Data

The historical data trend for Neovasc's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neovasc Construction In Progress Chart

Neovasc Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Construction In Progress

Get a 7-Day Free Trial

Neovasc Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Construction In Progress	Get a 7-Day Free Trial															-	-	-	-	-

Neovasc Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Neovasc (TSX:NVCN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neovasc Inc (TSX:NVCN) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

13562 Maycrest Way, Suite 5138, Richmond, BC, CAN, V6V 2J7

Website

https://www.neovasc.com

Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.